Selim Syed, Managing Director at Mizuho, joins Worldwide Exchange to give his thoughts on why more than 20% of NASDAQ Biotech Index’s members are trading for less than cash, a figure than hasn’t existed in data since 2002.
Selim Syed on the future of biotech companies amid sector drop
Tweet on Twitter
Share on Facebook
Pinterest
